













Novel Growth Partners

Existing capital market structure does not support the majority of entrepreneurs.

"Private institutional capital – bank lending and venture capital – dominate the capital landscape and receive the greatest attention in the research. Yet at least 83 percent of entrepreneurs do not access bank loans or venture capital."

Kauffman Foundation

The State of Access to Capital for Entrepreneurs February 2019

"...the existing venture capital industry only serves 1% of the entrepreneurs in the country, and we need innovators like Novel Growth Partners to develop solutions for the other 99%.

Ross Baird

Author of "The Innovation Blind Spot" President of Village Capital






Novel Growth Partners

The odds are against raising institutional venture capital for most entrepreneurs

In 2018 only 5536 out of more than 500,000 new companies received VC institutional investment with only 25% of those being early stage investments



PwC | CB Insights MoneyTree™ Report Q4 2018



Novel Growth Partners

Early stage companies have limited options for capital and are left in "no man's land".





Novel At a Glance

Transforming access to capital for underserved capital markets







Novel, a unique Revenue Based Investing (RBI) fund driven by compelling market insights






An approach that works for more companies

Revenue based investing (RBI) fits between equity VC and traditional debt

- Initial investment of \$100K to \$500K in entrepreneur-friendly growth capital for B2B software companies. (Max \$1M/Co)
- Investments of up to 30% of company ARR.
- Company returns capital to Novel on a set monthly royalty payment of between 4% and 8% of gross cash receipts.
- Royalties are capped at 1.5X to 2.2X the capital invested within a 3yr to 5yr timeline.
- Nominal warrants between 0.5% and 2%.
- Amount invested, royalty, cap and warrants are dependent on individual company's profile.





Who we invest in?


Emerging B2B software companies with coachable founders





Novel insights on early stage companies

Novel's Growth Bootcamp delivers proven tactical support for companies









Cost of Capital - Novel Vs Other Options

Novel offers meaningful capital at a reasonable cost to early stage companies

Type	Bank	Novel	Angels	VC
Key Benefits	Low Cost	Moderate costPayment Flexes	Low Upfront CostPayback at Exit	Low Upfront CostLarge checksPayback at Exit
Challenges & Constraints	 Generally not available to early stage ventures Collateral required Fixed payments Limited \$ (% of Receivables) 	 Must have revenue Needs to be close to profitability 	 Multiple relationships/terms to negotiate (Syndicate) Soft circled money waiting for a lead Small individual checks Several months to do deal 	 Few early stage ventures get investment 6 to 8 months average lead time 100%+ Annual growth expectations Requires a lead VC Complex Due Diligence Valuation negotiation
Expected Return	1.25X	1.5X to 2.2X	1.2X(Conv. Note) & 5.0X+(Equity)	10X+



Why entrepreneurs partner with Novel

Capital and expert operating support in a single platform

Simple and Transparent Fundraising Process

- Fast investment decision and funding in 45 to 60 days.
- Larger investments available as you grow.
- Fixed royalty percentage. You are not stuck to a fixed payment; it flexes with monthly cash flow.
- We play well with others. We can invest alongside angels, equity VCs or even venture debt.



Creating Entrepreneur Optionality

- Capped return. You know your total cost of capital at the beginning.
- No board oversight required.
- No exit required. Exit your company on your own timeline and your own terms.
- No personal collateral required. No personal guarantees.

More than just Capital

- We have been in your shoes. Our team has real world entrepreneurial/operational expertise.
- Novel's Growth Bootcamp and best practices make you a more valuable company.
- Interests are aligned with entrepreneur. No unnatural growth expectations. We both want growing, sustainable revenue.





Disclaimer



Confidentiality

This presentation contains confidential, proprietary information of Novel Growth Capital (NGP) and is furnished in confidence solely to the recipient for the specific purpose of evaluating the recipient's potential to receive investment from NGP (the "Permitted Purpose"). By accepting this presentation, the recipient agrees that, without the prior written consent of NGP, the recipient shall not (i) copy, distribute, make available or otherwise disclose any information in this presentation to other persons or (ii) use any such information for any purpose other than the Permitted Purpose. In addition, the recipient understands and acknowledges that: (x) NGP is providing the information contained herein as a courtesy and not pursuant to any contractual or other obligation to the recipient or any other person; (y) by providing such information at this time, NGP is not creating and is not intending to create any type of obligation to provide similar information at any time in the future; and (z) NGP has no duty to update such information and may decide not to provide the same type of information in the future.

Not an Offer

This presentation is not an offer to sell any securities or a solicitation of an offer to buy any securities. This presentation is qualified in its entirety by the more detailed information contained in the Subscription Agreement and governing documents of NGP. For more information on NGP 's investment strategy and risks, please read the Revenue Financing Agreement and governing documents. Any decision to make an investment in NGP should be based solely on the information in the Subscription Agreement for and the governing documents of NGP. This presentation is not intended to constitute legal, tax or accounting advice or an investment recommendation. Prospective and existing investors should consult their own advisers about such matters.

Projections and Future Performance

This presentation may include information about projections of anticipated future performance or results of NGP and other forward-looking statements. These projections and forward-looking statements are based on expectations, beliefs, assumptions, estimates and projections about market conditions as well as the anticipated performance of such entities. The projections and forward-looking statements included herein, or otherwise made orally or in writing from time to time, are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict, as well as factors that are beyond any NGP's control. NGP makes no express or implied representation or warranty as to the attainability of any of the projections or other forward-looking statements contained herein and no assurance can be given that NGP will achieve the financial results set forth in the projections or other forward-looking statements. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such projections and forward-looking statements, and such differences may be material and adverse to NGP. NGP does not intend to update any projections or forward-looking statements in making investment decisions.

Accuracy

The information in this presentation has not been audited or verified by any third party and is subject to change at any time without notice. Certain information contained herein was based on or obtained or derived from data published or prepared by other parties (collectively, "Third-Party Information"). While such sources are believed to be reliable, NGP or any of their respective directors, managers, officers, employees, partners, shareholders, members or agents assumes any responsibility for the accuracy of any Third-Party Information. NGP does not make any representation or warranty, express or implied, as to the accuracy, fairness, correctness, reasonableness, or completeness of any of the information contained herein (including but not limited to any Third-Party Information or any opinions contained in this presentation). NGP shall have no liability to any recipient of this presentation or any other person relating to or resulting from the use of or reliance on any such information contained herein or any errors therein or omissions therefrom. Unless otherwise noted, information included herein is presented as of the date hereof, and NGP has no responsibility to update any of the information provided in this summary document.

Third-Party Trade Names

This presentation may contain trade names, trademarks or service marks of other companies. NGP does not intend the use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of, such other parties.



Founding Partners

Complementary experience. Deep operational expertise.

Keith HarringtonFounder & Managing Director



- Former Managing Director at KBA, led investments in digital health, biotech for \$591M state-sponsored fund.
- Engineering and M&A leadership roles at Birch
 Telecom from startup to nearly \$300M in revenue.
- Advised hundreds of entrepreneurs through work with Larta Institute, TechStars, Upstart Partners, Pipeline.
- Venture Capital Executive Program, Berkeley / MBA,
 Indiana University / BS, Park University.
- Kauffman Fellow.

Carlos Antequera Founder & Managing Director



- Co-Founder and CEO of Netchemia (sold to PeopleAdmin), grew to \$15M in revenues and over 100 employees serving 3500 school districts, led three acquisitions, raised \$850K from angels and \$6.5M from institutional investors.
- Chief Product Officer/Chief, Corporate Strategy at PeopleAdmin, completed two acquisitions in collaboration with Vista Equity Partners.
- Active angel investor in ten startups, LP in VC & PE funds.
- MBA, University of Kansas / BS, Computer Science, Washburn University.
- Kauffman Fellow, Pipeline Fellow, Mentor for TechStars & Village Capital.